X-Linked Retinitis Pigmentosa

At 12 months, data from the phase 1/2 study of AAV5-RPGR gene therapy for RPGR-associated X-linked retinitis pigmentosa showed significant improvement in retinal sensitivity and functional mobility with the low and intermediate doses.

Nine-month data from a phase 1/2 clinical trial of AAV-RPGR gene therapy for X-linked retinitis pigmentosa showed clinically meaningful improvement in retinal sensitivity and vision-guided mobility.

Applied Genetic Technologies Corporation announced an update on the proposed design of an upcoming phase 2/3 trial for its X-linked retinitis pigmentosa clinical program, according to a press release.

Applied Genetic Technologies Corporation has received written feedback from the FDA about its potential X-linked retinitis pigmentosa treatment and updated its development plan accordingly, according to a press release.

Applied Genetic Technologies Corporation has completed enrollment in all dose groups for adult patients with achromatopsia in its phase 1/2 clinical programs, according to a press release.

The European Medicines Agency has granted priority medicines and advanced therapy medicinal product designations for AAV-RPGR, an investigational gene therapy treatment for X-linked retinitis pigmentosa, according to press releases from MeiraGTx Holdings and Janssen Pharmaceuticals, which are jointly developing the therapy.

Enrollment is complete in the two highest dose groups in a phase 1/2 clinical trial evaluating an adeno-associated virus-based gene therapy for the treatment of X-linked retinitis pigmentosa, according to a press release from Applied Genetic Technologies Corporation.